Triomics Raises $22M to Scale Oncology AI for Early Cancer Detection and Treatment

Triomics has secured $22 million in Series B funding to expand its oncology AI platform, which is designed to detect and treat cancer at earlier stages. The round was led by Battery Ventures, with participation from previous investors Nexus Venture Partners, Lightspeed, and Y Combinator, as well as new backers from Oncology Ventures and Precision Health Informatics. This investment is a significant vote of confidence in Triomics' ability to revolutionize cancer detection through AI, potentially saving countless lives by identifying cancers earlier when they are more treatable.